Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unleashing Chk1 in cancer therapy

1 Jul 2011

Abstract excerpt

The checkpoint kinase 1 (Chk1) is one of the major players in the signal transduction pathway set in motion in response to DNA damage which activates different cell cycle checkpoints including the G 1/S, the intra-S, G 2-M and the mitotic spindle checkpoint, contributing to the maintenance of genomic stability. Chk1 is considered a good molecular target to inhibit, in combination with other anticancer agents, to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21610326
DOI: 10.4161/cc.10.13.16398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unleashing Chk1 in cancer therapyPMID 21610326Read ↗

Chk1 Inhibitors for Novel Cancer TreatmentSemantic proximity Read ↗

Novel regulation of checkpoint kinase 1: Is checkpoint kinase 1 a good candidate for anti‐cancer therapy?Semantic proximity Read ↗

Novel Checkpoint 1 InhibitorsSemantic proximity Read ↗

Reality CHEK: Understanding the biology and clinical potential of CHK1Semantic proximity Read ↗

Chk1 and Chk2 kinases in checkpoint control and cancer.Semantic proximity Read ↗

Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancerSemantic proximity Read ↗

Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer CellsSemantic proximity Read ↗

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1Semantic proximity Read ↗

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in CancerSemantic proximity Read ↗

DNA damage checkpoint kinases in cancerSemantic proximity Read ↗

Checkpoint kinase inhibitors: a review of the patent literatureSemantic proximity Read ↗

The Chk2 protein kinase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.